| Title： | The CACM experts consensus for expert consensus on the clinical application of Longxin capsule in the treatment of ischemic stroke |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians in hospitals and primary medical and health institutions at all levels across the country (professionals of traditional Chinese medicine, western medicine, and integrated traditional Chinese and western medicine) |
| Evidence classification method： | This consensus adopts the GRADE system, an internationally recognized recommendation standard for grading evidence. The formation of expert consensus opinion adopts the nominal group method, which mainly considers six factors: evidence quality, efficacy, safety, economy, patient acceptability and others. |
| Development unit： | Xiyuan Hospital of Chinese Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Traditional Chinese Medicine, Institute of Clinical Basic Medicine of Chinese Academy of Chinese Medical Sciences, Yunnan Yongan Pharmaceutical Co., Ltd. |
| Registration time: | 2022-08-02 |
| Registration number： | PREPARE-2022CN440 |
| Purpose of the guideline: | To further clarify the efficacy of Longxinsu Capsules in the treatment of ischemic stroke, dosing schedule and timing, dosage and course characteristics, safety issues, etc., in order to improve clinical efficacy, promote rational drug use, and reduce drug risks. |
